We recently published a list of Top 10 Stocks to Buy According to 12 West Capital Management. In this article, we are going ...

Signaturefd LLC lifted its holdings in Repligen Co. (NASDAQ:RGEN – Free Report) by 172.2% in the 4th quarter, according to ...

Repligen’s strong growth and bioprocessing expansion position it for success. Find out why RGEN stock is a Buy, with a $175 ...

Envestnet Portfolio Solutions Inc. lowered its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 2.1% during the fourth quarter, according to the company in its most recent Form 13F ...

This quarter, Repligen’s $167.5 million of revenue was flat year on year and in line with Wall Street’s estimates. Looking ahead, sell-side analysts expect revenue to grow 9% over the next 12 ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Evercore ISI initiated coverage of Repligen (RGEN) with an In Line rating and $155 price target The firm sees the company as a high quality ...

WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc ...

Repligen (NASDAQ:RGEN), a bioprocessing technology company, announced its earnings for the fourth quarter on Feb. 20. Its adjusted earnings per share (EPS) of $0.44 exceeded analysts' consensus ...

Repligen Corporation RGEN reported fourth-quarter 2024 adjusted earnings per share of 44 cents, which beat the Zacks Consensus Estimate of 41 cents. The company had recorded adjusted earnings of ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $181.67, a high estimate of $205.00, and a low estimate of $155.00. Highlighting a 7.12% decrease, the ...

On Tuesday, Repligen Corporation (NASDAQ:RGEN) purchased 908 Devices Inc.’s (NASDAQ:MASS) desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.